Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology by Shapiro, David A. et al.
Aripiprazole, A Novel Atypical Antipsychotic Drug with a
Unique and Robust Pharmacology
David A Shapiro1, Sean Renock1, Elaine Arrington2, Louis A Chiodo3, Li-Xin Liu3, David R Sibley4, Bryan L
Roth1,5,6,* and Richard Mailman2
1Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, OH, USA; 2Department of Psychiatry and
Pharmacology and Neurobiology Curriculum, the University of North Carolina School of Medicine, Chapel Hill, NC, USA; 3Department of
Pharmacology, Texas Tech University Health Science Center, Lubbock, TX, USA; 4National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Bethesda, MD, USA; 5NIMH Psychoactive Drug Screening Program, Case Western Reserve University Medical
School, Cleveland, OH, USA; 6Department of Neurosciences, Case Western Reserve University Medical School, Cleveland, OH, USA
Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders. The current clinically approved
atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for
5-HT2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)). Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug
that is reported to be a high-affinity D2-dopamine receptor partial agonist. We now provide a comprehensive pharmacological profile of
aripiprazole at a large number of cloned G protein-coupled receptors, transporters, and ion channels. These data reveal a number of
interesting and potentially important molecular targets for which aripiprazole has affinity. Aripiprazole has highest affinity for h5-HT2B-,
hD2L-, and hD3-dopamine receptors, but also has significant affinity (5–30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-
HT7), as well as a1A-adrenergic and hH1-histamine receptors. Aripiprazole has less affinity (30–200 nM) for other G protein-coupled
receptors, including the 5-HT1D, 5-HT2C, a1B-, a2A-, a2B-, a2C-, b1-, and b2-adrenergic, and H3-histamine receptors. Functionally,
aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors.
Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type
selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending
upon the cell type and function examined. This mixture of functional actions at D2-dopamine receptors is consistent with the hypothesis
proposed by Lawler et al (1999) that aripiprazole has ‘functionally selective’ actions. Taken together, our results support the hypothesis
that the unique actions of aripiprazole in humans are likely a combination of ‘functionally selective’ activation of D2 (and possibly D3)-
dopamine receptors, coupled with important interactions with selected other biogenic amine receptorsFparticularly 5-HT receptor
subtypes (5-HT1A, 5-HT2A).
Neuropsychopharmacology (2003) 28, 1400–1411, advance online publication, 21 May 2003; doi:10.1038/sj.npp.1300203 .
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INTRODUCTION
Schizophrenia, a neuropsychiatric disorder affecting more
than 1% of the world’s population, is a devastating and
costly disease. As of 1991, it was estimated that costs
associated with schizophrenia in the United States ap-
proached $65 billion per year (Wyatt et al, 1995). Costs are
high because schizophrenia is a chronic disease, it affects
people in their youth, and treatment often requires frequent
and intensive hospitalization and outpatient care. Schizo-
phrenia is characterized by the appearance of delusions and
hallucinations (positive symptoms), but may involve a
variety of other symptoms including decreased social
functioning and speech, lack of motivation, poor hygiene,
and disorganization (all negative symptoms), as well as
cognitive impairment.
Effective medication-based treatments for schizophrenia
have been available for more than four decades. Early
therapies were based on what are now called typical
antipsychotics (eg chlorpromazine, haloperidol, and flu-
phenazine). These drugs were effective in reducing the
positive symptoms in 70–80% of schizophrenics, but tended
to cause acute extrapyramidal side effects (EPS) such as
Parkinsonism and acute dystonias, a lack of improvement
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(or a worsening) of negative symptoms, elevation of serum
prolactin levels, and (with chronic use) the debilitating
neurological side effect tardive dyskinesia. A common
feature of typical antipsychotic drugs is their affinity for
D2-dopamine receptors, typically in the low nanomolar
(o2.0 nM) range (Creese et al, 1976)
Clozapine, the prototypical atypical antipsychotic, was
reintroduced in the late 1980s following a pivotal study
demonstrating its effectiveness in treatment-resistant schi-
zophrenia (Kane et al, 1988). Since then, other atypical
antipsychotic drugs from several chemical classes, including
dibenzodiazepines (clozapine and quetiapine), thienoben-
zodiazepines (olanzapine), benzisothiazolyl piperazines
(ziprasidone), and benzisoxazoles (risperidone), have been
introduced. Unlike the typical antipsychotics, it has been
difficult to find a common mechanism explaining the
actions of these drugs. With the exception of quetiapine, the
atypicals have 5-HT2A/D2 affinity ratios grater than 10
(Meltzer et al, 1989), but they also interact with other
receptors from the serotonin (5-HT1A, 5-HT2C, 5-HT6,
5-HT7) (Roth et al, 1992, 1994, 1998), dopamine (D3, D4)
(Roth et al, 1995; Sokoloff et al, 1990; Van Tol et al,
1991), muscarinic cholinergic (Stanton et al, 1993; Zeng
et al, 1997), and histamine families (Kroeze et al, 2003;
Roth et al, in press). In fact, the useful properties of the
atypicals may depend on simultaneous effects caused by
interactions with multiple G protein-coupled receptors
(GPCRs) (Roth, 1994, 2000). From this perspective, it is not
surprising that atypical antipsychotic drugs are effective in
bipolar and schizoaffective disorders and depression (Ghae-
mi et al, 2000; Narendran et al, 2001; Sanger et al, 2001).
Recently, the FDA approved aripiprazole, a new atypical
antipsychotic drug (Inoue et al, 1997; Inoue et al, 1996;
Oshiro et al, 1998) that is proposed to differ in mechanism
of action from other atypical antipsychotic drugs. Aripi-
prazole has high affinity for D2- and D3-dopamine and
5-HT7 serotonin receptors (Lawler et al, 1999). There has
been a long-standing hypothesis that D2 partial agonists
would be of particular utility in schizophrenia (Tamminga,
2002), and the developers of aripiprazole have proposed
that the novel and improved clinical profile of aripiprazole
is caused by the partial agonist properties at D2-dopamine
receptors that result in ‘dopamine stabilization’ (Burris et al,
2002; Inoue et al, 1996). Conversely, it has been suggested
(Lawler et al, 1999) that aripiprazole is not simply a partial
agonist, but a drug whose D2 functional effects were
dependent on the cellular location (and signaling proteins)
of the targeted D2 receptor, a phenomenon termed
‘functional selectivity’ (Kilts et al, 2002; Lawler et al, 1999;
Mottola et al, 2002) or ‘agonist trafficking’ (Kenakin, 1995).
Whatever the mechanism, aripiprazole has been shown to
be effective in treating the positive and negative symptoms
of schizophrenia with a low incidence of side effects
including minimal short-term weight gain, low liability for
inducing movement disorders, and reductions (rather than
elevations) in plasma prolactin levels (Goodnick and Jerry,
2002; Goodnick et al, 2002; Kane et al, 2002).
To discover the mechanisms responsible for the favorable
actions of aripiprazole in schizophrenia, we conducted a
comprehensive pharmacological profiling of aripiprazole at
a large number of cloned human molecular targets
including GPCRs, ion channels, protein kinases and
transporters. We discovered that aripiprazole has a more
robust pharmacological profile than previously suspected,
including moderate-to-high affinity for a large number of
human cloned biogenic amine GPCRs. The current data also
demonstrate that aripiprazole can have partial agonist
properties at D3-dopamine, and 5-HT1A, 5-HT2A and
5-HT2C serotonin receptors. Finally, consistent with the
notion that aripiprazole is not a simple partial agonist, we
show that it can appear to be a typical antagonist in many
D2L-dopamine functional assays, suggesting the need for
further studies on the ‘functional selectivity’ properties of
the drug.
METHODS
Radioligand Binding Assays
A large number of transiently and stably transfected cloned
human cDNAs, obtained via the resources of the National
Institute of Mental Health Psychoactive Drug Screening
Program (NIMH-PDSP), were used for radioligand binding
and functional assays as previously detailed (Rothman et al,
2000; Tsai et al, 2000). Conditions for radioligand binding
assays, along with KD values for standard compounds, are
listed in Table 1. In initial screening assays, aripiprazole was
tested at a concentration of 10 mM in quadruplicate at a
large number of GPCRs, ion channels, and transporters. For
molecular targets at which 450% inhibition was measured,
Ki determinations were obtained using at least six
concentrations of aripiprazole; Ki values were calculated
in quadruplicate using GraphPad Prism (GraphPad Soft-
ware, San Diego California, USA). [125I]DOI competition
assays were performed as previously described (Choudhary
et al, 1992) with the following changes: 12 dilutions of
aripiprazole spanning a range of 0.01–3000 nM were
incubated with [125I]DOI (0.3 nM) in total volumes of
0.25 ml at 251C for 1 h with 5–20 mg of membrane protein in
binding buffer (50 mM Tris buffer, pH 7.4, 0.5 mM EDTA,
10 mM MgCl2). Membranes were harvested with a Brandel
cell harvester by three ice-cold washes onto polyethylenei-
mine-pretreated (0.3%) Whatman GF/C filters. Radioactiv-
ity bound to filters was quantified by liquid scintillation
counting.
PI Hydrolysis Assays
PI hydrolysis experiments were performed as previously
described, with minor changes (Bhatnagar et al, 2001; Gray
et al, 2001; Shapiro et al, 2000). Briefly, PO1C, GF62, or C6-
glioma cells were grown in T75 flasks to 80% confluency,
and plated into 24-well plates with Dulbecco’s modified
Eagle’s medium containing 10% dialyzed fetal calf serum.
After 24 h, media were aspirated and replaced with a serum-
free, inositol-free basal Eagle’s medium containing [3H]in-
ositol (1 mCi/ml). After 24 h, media were aspirated and
replaced with 1.0 ml of a modified Krebs buffer (118 mM
NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 1.2 mM
NaH2PO4, 24 mM NaHCO3, 11 mM dextrose, 18 mM LiCl)
preincubated to 371C and equilibrated with 5% CO2. Seven
concentrations of test compounds in triplicate were applied
in a total volume of 1.0 ml per well and incubated 1 h. The
solution was then quickly aspirated, replaced with 1.0 ml of
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a stop solution (formic acid/dH2O 1 : 100). After 20 min, the
stop solution containing the accumulated inositol phos-
phates (PIs) was added to columns containing 1 ml of anion
exchange resin (formate form) and washed with 12 ml of
water followed by 10 ml of 5 mM sodium borate/50 mM
sodium formate (Roth et al, 1986). Total PIs were eluted with
10 ml of 0.1 M formic acid/0.2 M ammonium formate into
vials containing 3a70B liquid scintillation cocktail (Research
Products International, Elk Grove Village, IL), and radio-
activity was measure by liquid scintillation counting.
Table 1 Affinities for Aripiprazole and Reference Compounds at Various Receptors, Channels and Transporters
Receptor Cold ligand 3H-ligand
KD
(nM)
Assay conc.
(nM)
Aripiprazole
Ki (nM)
5-HT1A WAY 100,635 8-OH-DPAT 1 0.5 5.67 0.8
5-HT1B Ergotamine GR125743 0.3 0.3 8307 260
5-HT1D Ergotamine GR125743 0.3 0.3 687 11
5-HT1E 5-HT 5-HT 7.2 3 80007 5000
r5-HT2A Chlorpromazine Ketanserin 0.8 0.5 227 4
5-HT2A Chlorpromazine Ketanserin 2 1 8.77 2.0
5-HT2A Chlorpromazine [125I]DOI 2.5 0.2 357 4
5-HT2B Norfenfluramine LSD 10 5 0.367 0.11
r5-HT2C Chlorpromazine Mesulergine 1.2 0.5 767 8
5-HT2C VGI
a Chlorpromazine Mesulergine 1.7 1 1807 37
5-HT2C INI
a Chlorpromazine Mesulergine 1.7 1 757 14
5-HT2C VGI
a Chlorpromazine [125I]DOI 3 0.2 977 100.0
5-HT2C INI
a Chlorpromazine [125I]DOI 3 0.2 227 11
r5-HT3 LY-278,584 Zacopride 0.3 0.3 6307 110
5-HT5A Ergotamine LSD 1.6 1 12407 280
5-HT6 Chlorpromazine LSD 1.5 1 5707 95
5-HT7 Chlorpromazine LSD 2 1 10.37 3.7
D1 SKF38393/Fluphenazine SCH23390 0.35 0.2 19607 670
D2L Haloperidol N-methylspiperone 0.5 0.2 0.747 0.09
D2 Haloperidol N-methylspiperone 0.4 0.2 3.37 1.1
D3 Chlorpromazine N-methylspiperone 0.4 0.2 9.77 5.4
D3 Chlorpromazine N-methylspiperone 0.4 0.2 1.07 0.40
rD4 Chlorpromazine N-methylspiperone 0.5 0.2 5107 93
D5 SKF38393/Olanzapine SCH23390 0.3 0.2 25907 1350
MOR Naloxone Diprenorphine 0.2 0.2 410 000
DOR Naltrindole Diprenorphine 0.2 0.2 410 000
KOR Naloxone Bremazocine 4 2 410 000
SERT Fluoxetine Citalopram 0.8 0.5 10807 180
NET Nortriptyline/imipramine Nisoxetine 1.2 0.5 20907 750
DAT 40 ,40-Diflouro-3a (diphenyl-methoxy)
tropane HCl
GBR12935 1 0.5 32207 660
H1 Chlorpheniramine Pyrilamine 3.6 1 25.17 2.6
H2 Me-histamine Tiotidine 10 0.5 410 000
gpH3 Histamine Me-histamine 1 0.5 2247 164
H4 Clozapine Histamine 10 5 410 000
rBZP Diazepam RO 15-1788 0.8 0.4 410 000
rGABA-A GABA Muscimol 3 410 000
rGABA-B GABA Baclofen 15 410 000
a-PKC PMA PDBU 1 0.5 410 000
g-PKC PMA PDBu 1 0.5 80007 2600
rNMDA (PCP site) PCP/ketamine TCP 1 0.5 40017 2177
a1A Urapidil Prazosin 0.2 0.2 25.77 5.0
a1B Corynanthine Prazosin 0.2 0.2 34.87 5.8
a2A Oxymetazoline Clonidine 2 2 74.37 11.7
a2B Prazosin Clonidine 2.0 2.0 1037 10.6
a2C Prazosin Clonidine 2.0 2.0 37.97 3.3
hb1 Atenolol Pindolol 0.1 0.1 1417 4.2
hb2 ICI-118,551 Pindolol 0.1 0.1 1637 15.0
M1 Pirenzepine QNB 0.2 0.5 67807 570
M2 Methoctramine QNB 0.2 0.5 35107 620
M3 4-DAMP QNB 0.2 0.5 46807 440
M4 Tropicamine QNB 0.2 0.5 15207 230
M5 Pirenzepine QNB 0.2 0.5 23307 383
Prostaglandin Ep3 PGE2 PGE2 2 1 410 000
Prostaglandin Ep4 PGE2 PGE2 2 1 410 000
Experiments were performed as described in Methods using the radioligands and unlabeled reference ligands listed above. Data
represent mean7 SEM of at least four separate experiments. All studies were performed with human cloned cDNAs expect where
specified; r¼ rat; gp¼ guinea-pig.
aRefers to mRNA editing isoform.
Aripiprazole, a novel atypical antipsychotic drug
DA Shapiro et al
1402
Neuropsychopharmacology
Effects of Aripiprazole on cAMP Production
Inhibition of forskolin-stimulated cAMP production.
Inhibition of forskolin-stimulated 30,50-cyclic adenosine
monophosphate (cAMP) production in stable D4 and
5-HT1A receptor expressing cell lines was measured as
previously reported (Lawler et al, 1999; Zhang et al, 1994).
In brief, cells were grown in 24-well plates and growth
media were replaced with fresh F12 medium containing
100 mM IBMX and 100 mM forskolin (all on ice) just prior to
experimentation. Serial dilutions (10-fold) of aripiprazole
ranging from 0.1 to 10.000 nM were added to the cells,
which were then incubated 20 min at 371C and 5% CO2. The
reaction was terminated by aspiration and the addition of
0.5 ml of ice-cold 3% trichloroacetic acid. Plates were chilled
for 1 h at 41C and spun at 1000 g for 15 min. cAMP was
quantified using a competitive binding assay adapted with
minor modifications (Nordstedt and Fredholm, 1990). For
measurement of cAMP content, trichloroacetic acid extracts
(40 ml) were added to reaction tubes containing cAMP assay
buffer (100 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM
EDTA). [3H]cAMP (1 nM final concentration) was added to
each tube, followed by cAMP-binding proteins (approxi-
mately 100 mg of crude extract from bovine adrenal cortex in
500 ml of cAMP buffer). The reaction tubes were incubated
on ice for 2 h, then harvested with a Brandel cell harvester
onto Whatman GF/C filters soaked in water. Filters were
allowed to dry, and bound radioactivity was quantified by
liquid scintillation counting. The concentration of cAMP in
each sample was estimated from a standard curve ranging
from 0.1 to 100 pmol of cAMP/assay.
Stimulation of cAMP production. Studies of the effects of
serotonin and aripiprazole at 5-HT6 and 5-HT7 receptors
were carried out in stable transfectants using methods
previously described (Max et al, 1995; Monsma et al, 1993;
Shen et al, 1993).
Electrophysiological Studies of D2L, D3, and D4
Receptors
Electrophysiology experiments were performed on MES-
23.5 cells stably transfected with D2L, D3, and D4 receptor
DNA, and drugs were administered in the bath as previously
described (Liu et al, 1999). D2L, D3, and D4 receptor
expression levels were 325, 360, and 470 fmol/mg respec-
tively, as originally reported by Liu et al (1999). In brief,
cover slips with attached MES-23.5 cell were transferred
from 24-well plates into a recording chamber, where cells
were perfused continuously at a flow rate of 1–2 ml/min by a
solution containing (in mM): NaCl, 135; KCl, 5.4; CaCl2, 1.8;
glucose, 20; HEPES, 5; plus 0.5 mM tetrodotoxin, adjusted to
pH 7.3 with Tris base, osmolarity adjusted to 320–
330 mOsmol. The dish was placed on the stage of an
inverted microscope (Zeiss ICM 405) and visualized using
Hoffman differential interference contrast optics at  400.
The recording headstage and electrode assembly were held
on an articulated arm of a three-position joystick-controlled
micromanipulator (MM-8000F, Activational System Inc.,
Warren, MI) during recording. The voltage-clamp in the
whole-cell configuration used an EPC-7/list patch clamp
amplifier (Adams-List Associates, Ltd., Westbury, NY).
Patch electrodes were fabricated from 1.5 to 1.6 OD
MicroHematoctrit capillary tubes (VWR Scientific) pulled
in a two-stage process on a Narishigie vertical puller (model
PA-81) and polished on a Narishigie microforge (model MF-
83). The holding potential and all voltage steps were
controlled by PCLAMP software and hardware (Axon
Instruments, Foster City, CA) using the CLAMPEX program.
The patch electrode solution contained the following (in
mM): KCl, 140; MgCl2, 2; CaCl2, 1; HEPES, 10; ATP, 2; cAMP,
0.25; and BAPTA, 0.5; adjusted to pH 7.3 with KOH,
osmolarity adjusted to 320–330 mOsmol. When tetraethy-
lammonium (TEA)-Cl (30 mM) was added to the bathing
medium, an equimolar concentration of KCl was removed.
All solutions were filtered through a 0.45mM membrane
filter. The patch electrode resistance ranged between 2 and
4 MO. The seal resistances were greater than 5 GO and after
membrane rupture the series resistance was between 4.3 and
10.0 MO (mean7 SEM: 7.17 1.8 megohms; n¼ 100) and the
level of capacitance compensation ranged between 10 and
22 pF (mean7 SEM and 15.97 6.5 pF; n¼ 100). All record-
ings were carried out at room temperature (18–221C). To
activate steady-state outward currents, the cells were clamped
at a holding potential of 60 mV and stepped to membrane
potentials between 80 mV and +90 mV. All drugs were
dissolved in the bath medium applied by a perfusion system.
GTPcS Binding Studies
The effects of drugs on [35S]-GTPg-S binding were deter-
mined in the presence and absence of agonist. Nonspecific
binding was defined as binding in the presence of 10mM cold
GTPg-S. Assay tubes contained 150–200 pM [35S]-GTPg-S,
binding buffer (50 mM HEPES, 100 mM NaCl, 4 mM MgCl2,
1 mM EDTA, 0.1% BSA, 0.1% ascorbic acid, pH 7.4 with
NaOH), 10mM GDP and varying concentrations of com-
pounds. CHO hD2L cell membranes (from cells expressing
4.6 pmol/mg receptor) were incubated with test compounds
for 15 min at 301C before addition of [35S]-GTPg-S. Assay
tubes continued to incubate for 30 min. The assay was
terminated by filtration with ice-cold wash buffer (50 mM
HEPES, 4 mM MgCl2, pH 7.4 with KCl). Filters were allowed
to dry, and 20ml of Packard MicroScint 20 scintillation
cocktail was added to each well. Radioactivity in each sample
was determined on a Packard Top Count NXT.
Data Analyses
Dose–response curves were analyzed by nonlinear regres-
sion using Prism 3.0 software (GraphPad, Inc., San Diego,
CA). Other data analysis used InStat 2.0 (GraphPad, Inc.,
San Diego, CA) or Prism 3.0 . Statistical significance
(a¼ 0.05) was determined either by ANOVA followed by the
listed post hoc test, or by two-tailed Student’s t-test. Some
receptor data were analyzed using LIGAND (Munson and
Rodbard, 1980).
RESULTS
Affinities of Aripiprazole for Dopamine, Serotonin, and
Other Receptors
The affinity of aripiprazole for a variety of receptors was
measured by competition radioligand binding assays.
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Table 1 summarizes the affinity values, and also lists the
radioligands and reference compounds used for each assay.
The affinities for human 5-HT2A and 5-HT2C receptors were
determined for both the inhibition of antagonist ([3H]ke-
tanserin) and agonist ([125I]DOI) radioligands.
Of interest are the relatively high affinities (Ki’s 10 nM or
less) of aripiprazole for the hD2, and rD3-dopamine, and h5-
HT1A, h5-HT2B, and h5-HT7 serotonin receptors
(Table 1). In addition, aripiprazole had moderate affinity
for the hH1 (25.1 nM) and gpH3-histamine (224 nM)
receptors, but low affinity (Ki410 000 nM) for the hH2-
and hH4-histamine receptors (Table 1). At all of the
adrenergic receptors tested, aripiprazole displayed moder-
ate affinity, highest at the a1A (Ki¼ 25.7 nM) and lowest at
a2B (Ki¼ 103 nM). Low affinities were observed at the m1–
m5 muscarinic receptors (Ki41 500 nM).
Of particular interest was the observation that aripipra-
zole’s affinity at D2 receptors was profoundly affected by
assay conditions. Thus, when rat D2-receptors were
expressed in HEK293 cells using an assay buffer containing
NaCl (50 mM Tris-HCl, pH¼ 7.4, 50 mM NaCl, 5 mM MgCl2,
0.5 mM EDTA) affinities were 6.8-fold lower than that
reported in rat striatal membranes, but a striking 62-fold
lower than those values obtained using stably transfected
CHO cells assayed in a Na-free buffer (Lawler et al, 1999).
The large effect of sodium ions on the measured affinity of
aripiprazole is likely due to the fact that sodium ions
decrease agonist affinities for D2-family receptors (Neve,
1991; Neve et al, 1991, 2001).
Functional Effects at Serotonin Receptors
The functional characteristics of aripiprazole were assessed
in several different cell systems, including some that were
also used for receptor screening, as well as others chosen
because of their functional utility. The first system studied
was the 5-HT1A receptor stably expressed in Chinese
Hamster Ovary cells. As shown in Figure 1, serotonin had
an EC50 of 4.5 nM, whereas aripiprazole was a low potency
(EC50¼ 329 nM) partial agonist at inhibiting forskolin-
stimulated cAMP production. At the 5-HT2A receptor
(Figure 2), aripiprazole was of even lower intrinsic activity.
Thus, in C6-glioma cells that express 5-HT2A receptors
without receptor reserve, aripiprazole caused increases in PI
hydrolysis only at the highest concentration tested (10 mM).
In GF62 cells, a cell line expressing the rat 5-HT2A receptor
with substantial receptor reserve, aripiprazole was a partial
agonist with an EC50 of 48 nM and intrinsic activity 12.7%
that of the full agonist 5-HT.
Next, aripiprazole was studied at 5-HT2B and 5-HT2C
receptors. In HEK-293 cells transiently expressing 5-HT2B
receptors 5-HT-stimulated PI hydrolysis with an EC50 of
41 nM (Figure 3). At 5-HT2B receptors, aripiprazole was an
inverse agonist that decreased PI hydrolysis to approxi-
mately half of basal levels, with an EC50 of 11 nM. In
contrast, aripiprazole was a partial agonist, albeit with
relatively high intrinsic activity, at serotonin 5-HT2C
receptors expressed in PO1C cells (r5-HT2c-VGV). As shown
in Figure 4, aripiprazole had an EC50 of 26 nM, and an
intrinsic activity 82% that of serotonin. Using COS-7 cells
transiently transfected with 5-HT2C INI receptor, aripipra-
zole was a weak full agonist, with an EC50 of
46257 2991 nM and efficacy matching that of the serotonin
control (data not shown). The effects of aripiprazole were
completely blocked by 100 mM ketanserin (a 5-HT2A/2C
antagonist), showing that the effects were indeed 5-HT2C
mediated.
The diverse effects caused by aripiprazole were seen again
in studies of serotonin 5-HT6 and 5-HT7 receptors. At the
5-HT6 receptor (Figure5, left), serotonin-stimulated cAMP
production in 5-HT6 stable transfectants. Aripiprazole
(10 mM) had not only no intrinsic activity of its own, but
also it blocked essentially all of the effects of serotonin. At
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Figure 1 Aripiprazole is a low potency partial agonist at the 5-HT1A
receptor stably expressed in 1ACHO cells. Inhibition of forskolin-
stimulated cAMP production was compared for serotonin and aripiprazole.
Data represent mean7 SEM from three separate experiments.
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Figure 2 Effect of aripiprazole on serotonin 5-HT2A receptors.
Functional effects of aripiprazole on PI hydrolysis were studied in the C-6
glioma line expressing an endogenous rat 5-HT2A receptor (C-6-5-HT2A)
and in GF62 cells transfected with the rat 5-HT2A (r5-HT2A). Response
data are plotted relative to maximal percentage stimulation by 5-HT in
each cell line, with the 5-HT curve being shown in the C-6 line for the sake
of clarity. Serotonin-stimulated PI hydrolysis in C-6-glioma cells with an
EC50¼ 211 nM, whereas aripiprazole caused partial stimulation only at the
highest tested concentration (10 mM). Similarly, in the GF62 cells,
aripiprazole was a partial agonist of extremely low intrinsic activity. Data
represent mean7 SEM of triplicate determinations from three (C-6) or
two (GF62) separate experiments.
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the 5-HT7 receptor (Figure 5, right), serotonin, as expected,
stimulated cAMP production in 5-HT7 stable transfectants.
Here, aripiprazole (10 mM) had barely measurable intrinsic
activity, and consistent with this conclusion, the same
concentration was able to reduce the effects of serotonin to
a level equal to aripiprazole alone. Thus, aripiprazole was an
antagonist at 5-HT6 receptors and a weak partial agonist at
5-HT7 receptors.
Functional Effects at Dopamine Receptors
Some prior studies have suggested that aripiprazole is a
partial agonist at D2 receptors (Burris et al, 2002), while
others have proposed that the drug is ‘functionally selective’
at D2 receptors (Lawler et al, 1999). The present experi-
ments thus tested aripiprazole in several different systems,
including many not previously studied. The first system
studied (Figure 6a) was the MES-23.5 cell line that had
stably transfected D2L receptors. As expected, quinpirole
caused a 75% increase in outward K+-currents, whereas
10 mM aripiprazole had no effect whatsoever, despite its
known affinity for this receptor. A similar pattern was seen
when GTPgS binding studies were carried out in D2L-
transfected CHO cells (Figure 6b). GTPgS binding was
increased markedly by both dopamine and quinpirole, and
the D2 antagonist domperidone could block completely the
effects of either dopamine or quinpirole. Conversely,
aripiprazole alone caused no significant effect, and was
equally effective as domperidone at blocking the actions of
either dopamine or quinpirole. Finally, in two different cell
lines stably expressing the D2L receptor, it was not possible
to inhibit forskolin-stimulated cAMP production at any
concentration of aripiprazole tested (data not shown). Thus,
aripiprazole was a pure antagonist in three different systems
expressing the D2L receptor.
On the other hand, we replicated the data reported by
Burris et al (2002) who found that aripiprazole was a
relatively efficacious partial agonist in HEK-293 cells
expressing the D2L receptor. As shown in Figure 7,
aripiprazole displayed an EC50 of 0.15 nM (pEC50¼
9.827 0.12) and an intrinsic activity of ca 75% compared
to 0.10 nM (10.07 0.05) and 90% for the reference
compound bromocriptine. In CHO cells expressing the
D2L receptor, aripiprazole had clear agonist activity,
although it was less potent (EC50¼ 18.3 nM; pEC50¼
7.77 1.2) than bromocriptine (EC50¼ 0.12 nM; pEC50¼
9.97 0.15).
MES-23.5 cells were used for studies of both the D3 and D4
receptors. As shown in Figure 8, and in contrast to the
effects at D2L receptors in this cell line, both quinpirole
(10 mM) and aripiprazole (10 mM) activated D3 receptors.
Moreover, the effects of aripiprazole were completely
blocked by the D2-like antagonist sulpiride (20 mM). When
this same MES-23.5 cell line is transfected with D4 receptors
(Figure 9, left), K+ currents were inhibited, rather than
stimulated by quinpirole. Aripiprazole (10 mM) caused the
same magnitude of effect (ca 30% decrease) as did
quinpirole (10 mM). In the same cell line (Figure 9, right),
aripiprazole was a partial agonist (EC50¼ 16 nM) at the D4
receptor vs inhibition of forskolin-stimulated cAMP pro-
duction. Dopamine also caused a dose-dependent inhibition
with an EC50¼ 363 nM.
DISCUSSION
Receptor Profile and Mechanism of Action
While it was known from prior studies that aripiprazole
interacted with dopamine and some serotonin receptors
(Lawler et al, 1999), the present data show that aripiprazole
has a novel and unexpectedly robust pharmacology,
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Figure 4 Effect of aripiprazole on serotonin 5-HT2C receptors in PO1C
cells. Data represent means and standard errors of triplicate determina-
tions. The single point demonstrates that 100 mM ketanserin can
completely block the effects of 10mM aripiprazole.
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Figure 3 Aripiprazole is an inverse agonist at the 5-HT2B receptor in
HEK-293 cells. Serotonin-stimulated PI hydrolysis in HEK 293 cells
transiently transfected with 5-HT2B receptors with an EC50 of 41 nM.
Aripiprazole decreased PI hydrolysis from a basal level of 61% down to a
low of 30% at 1000 nM, with an EC50 of 11 nM. Data represent
means7 SEM from three separate experiments.
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displaying functionally significant interactions at a large
number of biogenic amine GPCRs including D2-, D3-, and
D4-dopamine receptors, and 5-HT1A, 5-HT2A, 5-HT2B, 5-
HT2C, 5-HT6 and 5-HT7 serotonin receptors. The current
work clearly demonstrates that aripiprazole displays a
receptor binding profile substantially distinct from all other
approved atypical antipsychotics (ie clozapine, olanzapine,
quetiapine, risperidone, and ziprasidone).
Clozapine is now regarded as the prototypical atypical
antipsychotic drug, and is the treatment of choice for
treatment-resistant and treatment-intolerant schizophrenia
and related disorders because of its efficacy and relative lack
of EPS. Clozapine treatment also substantially decreases
suicidality among patients with schizophrenia, and it may
improve negative symptoms, cognition, and tardive dyski-
nesia (Kane et al, 1988; Meltzer et al, 1989; Meltzer and
McGurk, 1999). The molecular mechanism(s) responsible
for the actions of clozapine and other related atypical
antipsychotics (eg olanzapine, risperidone, quetiapine and
ziprasidone) are not proven, but the common view is that it
depends on a balanced occupancy of 5-HT2A serotonin and
D2-dopamine receptors (Meltzer et al, 1989).
All atypical antipsychotic drugs have a relatively complex
in vitro pharmacology with high affinities for a number of
serotonin receptors (eg 5-HT1A, 5-HT2A, 5-HT2C, 5-HT6 and
5-HT7 (Milan et al, 1992; Roth et al, 1992, 1994). At 5-HT2A
and 5-HT2C receptors, most atypical antipsychotic drugs are
inverse agonists (Rauser et al, 2001). Atypical antipsychotic
Figure 5 Antagonist effects of aripiprazole at 5-HT6 and 5-HT7 receptors in stable transfectants. (Left) 5-HT-stimulated cAMP production in 5-HT6 stable
transfectants. Aripiprazole (10 mM) blocked essentially all of the effects of serotonin at the 5-HT6 receptor, and had no intrinsic activity of its own. (Right) 5-
HT-stimulated cAMP production via 5-HT7 mechanisms, whereas aripiprazole (10 mM) had low intrinsic activity at the 5-HT7 receptor, and effectively
blocked the effects of serotonin.
Figure 6 Functional effects of aripiprazole at D2L receptors. (a) Quinpirole caused a 75% increase in outward K
+-currents in MES-23.5 cells stably
transfected with D2L receptors. Conversely, 10mM aripiprazole had no effect. (b) In D2L-transfected CHO cells, GTPgS binding was increased by both
dopamine and quinpirole. Conversely, aripiprazole caused no significant effect on its own, and like the D2 antagonist domperidone, could block the effects of
either dopamine or quinpirole. Data represents one of two experiments with identical results.
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drugs also interact, to a greater or lesser extent, with various
dopamine receptors including D3-dopamine (Sokoloff et al,
1990) and D4-dopamine (Roth et al, 1995; Van Tol et al,
1991) receptors. At present, it is unclear to what extent
binding to receptors other than D2-dopamine and 5-HT2A
serotonin receptors contributes to the actions of the atypical
antipsychotic drugs. In this regard, it is important to note
that aripiprazole has much higher affinity for the human
dopamine D2 receptor (0.74 nM) than other atypical
antipsychotic drugs, although its affinity is markedly
attenuated by sodium (Ki¼ 32.1 nM in the presence of
150 mM NaCl). Of the atypical antipsychotics, only risper-
idone is reported (in some systems) to show an affinity for
the human D2 receptor (0.3–4 nM) approximating that of
aripiprazole, while the other atypical antipsychotic drugs
have affinities for both rat and human D2 receptors in the
range of 3–800 nM (see on-line database at: http://kidb.
bioc.cwru.edu/pdsp.php and Arnt and Skarsfeldt, 1998).
This is of particular clinical relevance, since blockade of
mesolimbic D2 receptors is believed to be related to efficacy
against the positive symptoms of schizophrenia (Worrel
et al, 2000).
Aripiprazole displayed variable binding affinities for the
tested 5-HT receptors, ranging from 0.36 nM (5-HT2B) to
8mM (5-HT1E) (Table 1). With a Ki¼ 22.4 nM for human
5-HT2A receptors labeled with [
3H]ketanserin, aripiprazole
had 10–100-fold lower affinity for these receptors than all
other tested atypical antipsychotic drugs except quetiapine
(31 nM; see on-line database at: http://kidb.bioc.cwru.edu/
pdsp.php). Aripiprazole also had low affinity at 5-HT2C
receptors labeled with the antagonist [3H]mesulergine
(Ki¼ 428 nM), yet much higher affinity for agonist labeled
5-HT2A and 5-HT2C receptors (Table 1). Higher affinity for
agonist vs antagonist-labeled 5-HT2- receptors is character-
istic of agonists and partial agonists (Egan et al, 2000). This
may explain the higher potency aripiprazole has for
activating 5-HT2C receptors (23 nM) relative to its inhibition
of [3H]mesulergine binding (76 nM).
One of the greatest concerns associated with the use of
atypical antipsychotics is the propensity of the drugs to
induce weight gain in up to 40% of treated patients
(Richelson, 1999; Worrel et al, 2000). Long-term health
problems associated with the weight gain (including
cardiovascular disease, diabetes, and increased risk of
cancer) may be so severe as to contraindicate treatment in
some patients. Furthermore, the weight gain may be an
important factor in noncompliance. Retrospective studies
have concluded that clozapine and olanzapine treatments
offer the greatest risk of weight gain, although only
clozapine-induced weight gain appeared to be long term
and not easily controllable through intervention such as diet
and exercise. Of the atypical antipsychotic drugs currently
approved for use, risperidone presents an intermediate risk,
followed by sertindole and ziprasidone (Wirshing et al,
1999). The greatest single correlate for weight gain has been
antagonism of the H1-histamine receptor (Wirshing et al,
1999; Kroeze et al, 2003). The moderate binding affinity of
aripiprazole for the human H1-histamine receptor (25.1 nM)
predicts that aripiprazole will exhibit a minimal propensity
to induce short-term weight gain (Kroeze et al, 2003). The
results of ongoing clinical trials, however, should answer
this question conclusively.
Functional Effects at Target Receptors and the
‘Functional Selectivity Hypothesis’
D2-receptors. The functional findings in the current
work are of particular importance, since the actions of
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Figure 7 Aripiprazole is a partial agonist in cells stably expressing high
levels of the dopamine D2L receptor. HEK 293 and CHO cells stably
expressing the dopamine D2 receptor (Burris et al, 2002) were used to
assess the agonist actions of aripiprazole. Activities of aripiprazole and the
partial agonist bromocriptine were measured using inhibition of forskolin
(fsk)-stimulated cAMP production. Values along ordinate represent the
cAMP measured at each inhibitor concentration relative to uninhibited,
forskolin-stimulated assay wells, normalized to 100%. Data represent
mean7 SEM of triplicate determinations from one of three replicate
experiments having similar results.
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Figure 8 Strong agonist activity of aripiprazole at D3-linked K
+-currents
in MES-23.5 cells. Quinpirole (10 mM) or aripiprazole (10 mM) both
activated D3 receptors, and the effects of aripiprazole were completely
blocked by sulpiride.
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aripiprazole differ markedly across receptor systems. Thus,
in the present studies, aripiprazole was sometimes an
antagonist (eg at 5-HT6 and D2L), sometimes an inverse
agonist (eg 5-HT2B), sometimes a partial agonist (eg D2L),
and sometimes a full agonist (D3, D4). Aripiprazole was
frequently found to be a partial agonist, with an intrinsic
activity that could be low (D2L, 5-HT2A, 5-HT7), inter-
mediate (5-HT1A), or high (D4, 5-HT2C). We recognize (vide
infra) that in vitro assay systems may not accurately reflect
the actions of the drug in vivo, yet we feel the present data
do provide important clues as to the mechanism of action of
aripiprazole. This mixture of agonist actions at D2-
dopamine receptors is consistent with the hypothesis
proposed by Lawler et al (1999) that aripiprazole has
‘functionally selective’ actions. The ‘functional-selectivity’
hypothesis proposes that, depending upon the cellular
milieu (eg receptor and G protein complement and
concentration), a mixture of agonist/partial agonist/antago-
nist actions are likely (Kilts et al, 2002; Lawler et al, 1999;
Mottola et al, 2002). According to this hypothesis, agonists
may induce structural changes in receptor conformations
that are differentially ‘sensed’ by the local complement of G
proteins to induce a variety of functional actions depending
upon the precise cellular milieu. The diverse actions of
aripiprazole at D2-dopamine receptors are clearly cell-type
specific (eg agonism, antagonism, partial agonism), and are
most parsimoniously explained by the ‘functional selectiv-
ity’ hypothesis.
Indeed, the functional effects of aripiprazole have been
extensively studied at dopamine D2 receptors. Prior studies
have supported the notion that the unique clinical actions of
aripiprazole are the result of its partial agonist properties at
the D2L receptor (Burris et al, 2002; Inoue et al, 1996;
Tamminga, 2002). Burris et al (2002) have shown that in
CHO cells transfected with hD2L (500–1000 fmol/mg; see
Filtz et al, 1993), aripiprazole behaves as a classical partial
agonist. In this study, we were able to replicate the Burris
et al (2002) finding that aripiprazole has partial agonist
actions when using the identical cell lines. Conversely,
others (Lawler et al, 1999) concluded that the functional
properties of aripiprazole are affected markedly by cell type
and other variables to a much greater degree than by other
drugs. Thus, Lawler et al (1999) hypothesized that a
mechanism called ‘functional selectivity’/‘agonist traffick-
ing’ might be critical to the actions at the D2L receptor in
brain. Specifically, they suggested that the functional
characteristics of aripiprazole at a single receptor isoform
(eg the D2L) are highly dependent on the location of the
receptor (ie influenced by the signaling partners such as G
proteins). The current studies report data from a variety of
systems in which aripiprazole has not only no detectable
intrinsic activity, but in one of the systems is a complete
antagonist of both dopamine and quinpirole. It is unlikely
that the differential actions of aripiprazole as an agonist,
antagonist, or partial agonist were entirely due to differ-
ences in relative D2 receptor expression since aripiprazole
was an antagonist in cells with the highest level of
expression 4.6 pmol/mg) and a partial agonist in cells with
an intermediate level of expression (0.5–1 pmol/mg).
Instead, the current data are most parsimoniously explained
by the ‘functional selectivity’ hypothesis of Lawler et al
(1999).
5-HT2A/B/C receptors. Since 5-HT2C receptors have been
implicated in the control of depression, OCD, and appetite,
agonism at the 5-HT2C receptor might be associated with
therapeutic potential in obsessive compulsive disorder,
obesity, and depression (Martin et al, 1998). 5-HT2C
agonism has been demonstrated to induce anorexia via
enhancement of serotonergic neurotransmission via activa-
tion of 5-HT2C receptors (Vickers et al, 1999); it is
conceivable that the 5-HT2C agonist actions of aripiprazole
may, thus, be partly responsible for the minimal weight gain
associated with this compound in clinical trials. In terms of
potential action as an antiobsessional agent, it is worthwhile
noting that a variety of 5-HT2A/5-HT2C agonists have shown
promise as antiobsessional agents, yet many of these
compounds are hallucinogenic, presumably due to 5-HT2A
Figure 9 Differential functional effects of aripiprazole at D4-linked functions. (Left) Aripiprazole (10 mM) and quinpirole (10 mM) caused similar (30–35%)
decreases in K+ currents in MES-23.5 cells stably transfected with D4 receptors. (Right) Dopamine and aripiprazole both increased cAMP production in this
cell line, although aripiprazole (EC50¼ 16 nM) was of lower intrinsic activity than dopamine (EC50¼ 363 nM). All data represent mean7 SEM from three
separate experiments.
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activation (Roth et al, 1999). Based on data obtained using
C6-glioma cells, which express 5-HT2A receptors with
minimal receptor reserve, we conclude that aripiprazole
will function as a 5-HT2A antagonist in vivo. Thus,
aripiprazole has a favorable pharmacological profile in
being a 5-HT2A antagonist and a 5-HT2C partial agonist.
Based on this profile, one can predict that aripiprazole may
have antiobsessional and anorectic actions in humans.
The other member of the 5-HT2-receptor family that
aripiprazole has high affinity for is the 5-HT2B receptor.
Since agonism at 5-HT2B receptors is associated with
vavlular heart disease (Fitzgerald et al, 2000; Rothman
et al, 2000), it is important to determine whether
aripiprazole was an agonist or antagonist at 5-HT2B
receptors. The current data demonstrate that aripiprazole
is an inverse agonist at 5-HT2B receptors, and is thus
unlikely to induce valvular heart disease. On the other hand,
5-HT2B antagonism has been promoted as a pharmacologic
approach for treating migraine headadches (Hamel, 1999;
Johnson et al, 1998). This is because of the observation that,
during a migraine attack, activation of 5-HT2B receptors has
been reported to accompany a sudden rise in serotonin,
potentially resulting in activation of sensory neurons and
the onset of pain. It will be interesting to see whether the
potent antagonism (inverse agonism) of aripiprazole at the
5-HT2B receptor will translate into an effective antimigraine
therapy.
The prefrontal cortex contains large densities of both
5-HT1A and 5-HT2A receptors, located primarily on
pyramidal neurons. As cortical 5-HT2A receptors are
excitatory, and cortical 5-HT1A receptors are inhibitory, it
has been suggested recently that blockade of cortical 5-HT2A
receptors and/or functional 5-HT1A receptor agonism may
mediate the physiological balance between excitatory and
inhibitory inputs onto prefrontal pyramidal neurons
(Martin-Ruiz et al, 2001). In preclinical trials, 5-HT1A
selective agonists were capable of antagonizing (attenuat-
ing) neuroleptic-induced EPS in animal models (Ellenbroek
et al, 1994; Liebman et al, 1989). Based on this finding,
Feenstra et al (2001) examined the structure/affinity
relationship of a large panel of 5-HT1A receptor binding
an analogs. At least one of these analogs shows promise as
an antipsychotic drug in rodents and is being developed for
pharmacological study. Of the current atypical antipsycho-
tic drugs, ziprasidone is the only drug that binds with
similar affinity to aripiprazole at the 5-HT1A receptor. Thus,
5-HT1A partial agonism is not a common pharmacological
characteristic of atypical antipsychotic drugs. It remains to
be seen, then, whether 5-HT1A selective agonism, alone or in
combination with effective 5-HT2A antagonism, will be
efficacious in treating the various symptoms of schizo-
phrenia.
It is nonetheless clear that aripiprazole is an atypical
antipsychotic drug with a unexpectedly robust pharmacol-
ogy, and, thus, shows promise as the first in a new
generation of atypical antipsychotic drugs. The pharmaco-
logical profile of aripiprazole is consistent with a favorable
in vivo pharmacology in humans including a relatively low
propensity to induce either weight gain or EPS. It is also
possible that aripiprazole may prove to be effective in other
disorders based on the unusually broad pharmacologic
profile uncovered in this survey. The current data suggest
that the new class of drugs represented by aripiprazole may
work by being either dopamine-serotonin partial agonists¸
and/or by working through the mechanism of ‘functional
selectivity’/‘agonist trafficking’ (eg at the D2 and possibly
some 5-HT receptors). Our research clearly points to the
need for further studies on both multiple receptor targeting
and ‘functional selectivity’/‘agonist trafficking.’ Such me-
chanisms also open the door for other therapeutic indica-
tions for aripiprazole, including its use as a treatment for
migraine, obesity, obsessive-compulsive disorder and other
psychiatric conditions.
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